Warning: The NCBI web site requires JavaScript to function. more...
CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.
Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, Waag D, Adamovicz JJ.
J Immune Based Ther Vaccines. 2010 Feb 5;8(1):2.
Related citations
Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.
Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, Chen W, House RV, Sjöstedt A.
Vaccine. 2010 Feb 17;28(7):1824-31. Epub 2009 Dec 16.
A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.
Pechous RD, McCarthy TR, Mohapatra NP, Soni S, Penoske RM, Salzman NH, Frank DW, Gunn JS, Zahrt TC.
PLoS One. 2008 Jun 25;3(6):e2487.
Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW.
Microb Pathog. 2008 Feb;44(2):164-8. Epub 2007 Aug 21.
Azithromycin effectiveness against intracellular infections of Francisella.
Ahmad S, Hunter L, Qin A, Mann BJ, van Hoek ML.
BMC Microbiol. 2010 Apr 23;10:123.
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA.
Infect Immun. 2010 Oct;78(10):4341-55. Epub 2010 Jul 19.
Contribution of citrulline ureidase to Francisella tularensis strain Schu S4 pathogenesis.
Mahawar M, Kirimanjeswara GS, Metzger DW, Bakshi CS.
J Bacteriol. 2009 Aug;191(15):4798-806. Epub 2009 Jun 5.
Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.
Wu TH, Zsemlye JL, Statom GL, Hutt JA, Schrader RM, Scrymgeour AA, Lyons CR.
Vaccine. 2009 Jul 23;27(34):4684-93. Epub 2009 Jun 9.
Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence.
Qin A, Scott DW, Mann BJ.
Infect Immun. 2008 Jul;76(7):3086-92. Epub 2008 May 5.
Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG.
Lindgren H, Shen H, Zingmark C, Golovliov I, Conlan W, Sjöstedt A.
Infect Immun. 2007 Mar;75(3):1303-9. Epub 2007 Jan 8.
Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP.
Clin Vaccine Immunol. 2009 Apr;16(4):444-52. Epub 2009 Feb 11.
Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.
Klimpel GR, Eaves-Pyles T, Moen ST, Taormina J, Peterson JW, Chopra AK, Niesel DW, Carness P, Haithcoat JL, Kirtley M, Nasr AB.
Vaccine. 2008 Dec 9;26(52):6874-82. Epub 2008 Oct 16.
GroEL and lipopolysaccharide from Francisella tularensis live vaccine strain synergistically activate human macrophages.
Noah CE, Malik M, Bublitz DC, Camenares D, Sellati TJ, Benach JL, Furie MB.
Infect Immun. 2010 Apr;78(4):1797-806. Epub 2010 Feb 1.
Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.
Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH.
Infect Immun. 2008 Dec;76(12):5843-52. Epub 2008 Oct 13.
Animal models of Francisella tularensis infection.
Rick Lyons C, Wu TH.
Ann N Y Acad Sci. 2007 Jun;1105:238-65. Epub 2007 Mar 29. Review.
Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.
Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S.
Infect Immun. 2004 Aug;72(8):4494-502.
Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.
Andron LA II, Eigelsbach HT.
Infect Immun. 1975 Jul;12(1):137-42.
Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection.
Pyles RB, Jezek GE, Eaves-Pyles TD.
Infect Immun. 2010 Apr;78(4):1700-10. Epub 2010 Feb 1.
The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics.
Bina XR, Wang C, Miller MA, Bina JE.
Arch Microbiol. 2006 Sep;186(3):219-28. Epub 2006 Jul 14.
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.
Vaccine. 2008 Sep 26;26(41):5276-88. Epub 2008 Aug 8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on